M&A

Merck Ends Nemtabrutinib Development

Merck discontinued the nemtabrutinib BELLWAVE clinical development program, including three phase 3 trials, following an unfavorable benefit-risk assessment of BELLWAVE-011. Merck obtained nemtabrutinib through its approximately $2.7 billion acquisition of ArQule in 2019. The company continues to develop other hematologic oncology assets, including TERN-701 and MK-1045.

Written by Gosset from public sources. Source types: News article. Sources are available to Gosset users. Log in to see them.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call